<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

New Pediatric Leukemia Treatment Boosts Survival Rates with Fewer Side Effects

by The Denver Post | December 21, 2024
placeholder

A breakthrough leukemia treatment, blinatumomab, researched by CU Cancer Center Member Lia Gore, MD, at Children’s Hospital Colorado, is revolutionizing pediatric cancer care. The immunotherapy boosts survival rates to 96%, significantly reducing long-term side effects compared to traditional chemotherapy.

Topics: Press Coverage